Karyopharm Expects 2024 Sales Of $145M-$155M Versus Prior Guidance Of $145M-$160M And Consensus Of $152.352M

Karyopharm預計2024年銷售額爲14500萬至15500萬美元，低於之前的預測1.45億至16000萬美元以及市場預期的1.52352億美元。

Benzinga · 2024/11/05 20:34

2024 Financial Outlook

2024年財務展望。

Based on its current operating plans, Karyopharm has further narrowed its guidance for full year 2024 as follows:

根據目前的營運計劃，Karyopharm進一步縮小了2024財政年度的指導範圍如下：

Total revenue to be in the range of $145.0 million to $155.0 million as compared to the Company's prior guidance of $145.0 million to $160.0 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
U.S. XPOVIO net product revenue to be in the range of $110.0 million to $115.0 million as compared to the Company's prior guidance of $105.0 million to $120.0 million.
R&D and selling, general and administrative (SG&A) expenses to be in the range of $255.0 million to $265.0 million, which includes approximately $20.0 million estimated non-cash stock-based compensation expense, as compared to the Company's prior guidance of $250.0 million to $265.0 million.
The Company expects that its existing cash, cash equivalents and investments, the revenue it expects to generate from XPOVIO net product sales and its license agreements and ongoing disciplined expense management and cost saving measures, will be sufficient to fund its planned operations into the first quarter of 2026.

預計總營業收入將在$14500萬至$15500萬區間內，相比公司之前的指導範圍爲$14500萬至$16000萬。總營業收入包括美國XPOVIO淨產品營收和從合作伙伴獲得的許可、版稅和里程碑收入。
美國XPOVIO淨產品營收預計將在$11000萬至$11500萬區間內，相比公司之前的指導範圍爲$10500萬至$12000萬。
研發、銷售、一般和行政（SG&A）費用預計將在$25500萬至$26500萬區間內，其中包括約$2000萬的預計非現金股權補償費用，相比公司之前的指導範圍爲$25000萬至$26500萬。
公司預計其現有的現金、現金等價物和投資，來自XPOVIO淨產品銷售以及許可協議和持續的有節制的費用管理和節約措施產生的收入，將足以資助其計劃中的運營直至2026年第一季度。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

風險及免責聲明